Q-omics provides the consensus-scored TNFAIP8 profile across patient tissues and cancer cell-line models. TNFAIP8 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, TNFAIP8 is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, TNFAIP8 protein abundance shows 29,097 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight SKCM, HNSC, and LSCC as cancer lineages where TNFAIP8 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TNFAIP8 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TNFAIP8 survival associations across molecular data types. TNFAIP8 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (5) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TNFAIP8 RNA expression–survival associations across cancer types. High TNFAIP8 expression shows unfavorable associations in LGG and UVM, but favorable associations in SKCM, KIRC, CHOL and THYM. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for TNFAIP8 RNA expression.
This table summarizes TNFAIP8 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 7. The strongest signals are observed in HNSC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for TNFAIP8. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TNFAIP8 shows lower tumor expression in KICH, THCA and BRCA and higher tumor expression in HNSC, KIRP and KIRC. The HNSC box plot shows higher TNFAIP8 RNA expression in tumor versus normal tissue (log2 FC = +0.883, t-test p < 0.001).
This table shows molecular features associated with TNFAIP8 in patient tissues and cancer cell lines. In patient samples, TNFAIP8 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, TNFAIP8 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and SKIN.
